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COMMENT&RESPONSE
Breast Cancer Risk After Ovarian Stimulation
for In Vitro Fertilization
To the Editor The study by Dr van den Belt-Dusebout and
colleagues1 investigatedadebatedaspectof reproductivemedi-
cine:breastcancer risk followingovarianstimulationfor invitro
fertilization (IVF).2-5 The authors concluded that “these find-
ings are consistent with absence of a significant increase in
long-term risk of breast cancer among IVF-treated women.”1
However, some important points should be discussed.
For approximately 23% of women, subfertility diagnosis
and number of IVF cycles were collected using a question-
naire because medical records were not available. This high
rate threatens the reliabilityof results. It isnotpossible to com-
pare a detailed report of officialmedical recordswithdata de-
riving from subjective memory of treatments received many
years before. Thismay be a strong bias, because reproductive
medicine, IVF strategies, and the pharmacological protocols
have changed rapidly in the last decades.
Dates of diagnosis andhistologywere reportedbut unfor-
tunately not disease staging. It would be interesting to inves-
tigate if ovarian stimulationwith theuseof IVF techniques can
promote theoccurrenceofbiologicallydifferent typesofbreast
cancer, as in the case of tamoxifen-related endometrial can-
cer, a neoplasia with better prognostic profile and outcome.
Also, the authors reported that breast cancer risk de-
creasedwithmore IVFcycles (≥7comparedwith 1-2).Theysug-
gestedaspotential explanations thatwomentreatedwithmore
IVFcycles receivedmorehumanchorionicgonadotropinorhad
longer periods of down-regulationwith lowestradiol andpro-
gesterone levels, or that thewomen requiringmore IVF cycles
were inherently different. It is difficult to provide a definitive
conclusion because the clinical outcomes of IVF cycles were
not reported. The decreased risk among women treated with
many IVF cycles also could be related to the improvement of
ovarian function after repeated endocrine stimulations. In-
fertility and infertility-related nulliparitymust be considered
as risk factors for breast cancer, and prolonged treatment of
anovulatory or poor ovulatory cycles could be one approach
for restoringnormal ovarian activity and reducing breast can-
cer risk.
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In Reply Dr Tomao and colleagues are concerned that our re-
sultsmaybe biased because, for 23%of the studypopulation,
informationonsubfertilitydiagnosis andnumberof IVFcycles
was obtained from a self-administered questionnaire when
medical records were not available. We felt confident using
questionnairedata for subfertilitydiagnosis to limit theamount
ofmissingdata becausedeBoer and colleagues1 reported that
in the samestudypopulation, thevalidityof self-reported sub-
fertility causes was satisfactory.
For the most frequent subfertility diagnoses, tubal and
male subfertility (50% of all diagnoses), measures of agree-
ment (using the κ statistic)were0.79 for self-report vs0.71 for
medical record review. Also, adjustment for subfertility diag-
nosis did not change the risk estimates for the association be-
tween IVFandbreast cancer. Because themost important rea-
son for missing medical record data was that medical record
abstraction could not be performed (in 3 of 12 clinics),2,3 the
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absent data are likely missing at random. When comparing
questionnaire andmedical record information regardingnum-
ber of IVF cycles among women with both sources (n = 9769
[51%]), 80% of women were classified into the same cat-
egory. Therefore, it is unlikely that using self-reported subfer-
tility diagnosis and number of cycles for 23% would have bi-
ased the results.
Tomao and colleagues suggest that it would be interest-
ing to investigate whether ovarian stimulation for IVF can
promote the occurrence of biologically different types of
breast cancer, as in the case of tamoxifen-related endometrial
cancer. We agree this would be interesting; however, be-
cause IVF treatment was not associated with increased risk
of breast cancer, we considered it less relevant to examine
whether IVF treatment was associated with breast cancer
type. To investigate whether exposure to many IVF cycles
could be associated with decreased risk of specific breast
cancer types, larger numbers of women with breast cancer
would be needed.
We agree that the decreased breast cancer risk in women
treatedwithmany IVFcycles (≥7comparedwith 1-2)mightalso
be associatedwith the improvement of ovarian function after
repeated endocrine stimulations, or there could be other pos-
sible explanations. In the analyses,we adjusted for parity and
age at first birth as clinical outcomes of IVF, which were the
only confounding factors. Other clinical outcomes (ie, can-
celled cycles, ovarian hyperstimulation syndrome, poor re-
sponse to first IVF cycle, anddurationof gestation<24weeks)
did not influence the results. However, we did not havemea-
sures of estradiol and progesterone levels to draw definitive
conclusions.
In our study, infertility and infertility-related nulliparity
were not associated with increased risk of breast cancer. We
think that anovulatory or poor ovulatory cycles should be
treatedtorestorenormalovarianactivity ifwomenwishtohave
a child or are hindered by their irregular ovulatory cycles, re-
gardless of a potential reduction of breast cancer risk.
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Colorectal Cancer Screening
To the Editor To inform the recently updated guidelines
from the US Preventive Services Task Force (USPSTF) on
colorectal cancer (CRC) screening,1 Dr Lin and colleagues
conducted a meta-analysis of randomized trials of different
screening interventions, including flexible sigmoidoscopy.2
Unfortunately, the authors pooled different age groups in the
Norwegian Colorectal Cancer Prevention Trial (NORCCAP)3 to
calculate the summary mortality estimate for flexible sigmoi-
doscopy screening. Methodologically, we do not think this
approach is correct because pooling the age groups intro-
duced confounding by age.
In NORCCAP, individuals aged 55 to 64 years were
randomized to screening or usual care in a 1:3 ratio, and
individuals aged 50 to 54 years were randomized in a 1:5.4
ratio. The mean age was well balanced within each age
group. However, owing to uneven randomization ratios, indi-
viduals in the usual care group were, on average, younger
than those in the screening group (mean age, 56.1 years in the
usual care group and 56.9 years in the screening group). As a
result, a valid summary estimate of the trial data has to take
this imbalance into account.
To understand why this is necessary, consider both age
groups (50-54 years and 55-64 years) separately. The relative
risk (RR) for CRC mortality in the group aged 50 to 54 years
was 0.74 (95%CI, 0.40-1.35), and the RR in the group aged 55
to 64 yearswas 0.73 (95%CI, 0.55-0.97).3 However,when the
2 age groupswerepooled, the crudeRR for CRCmortalitywas
0.80 (95% CI, 0.62-1.04).2
Lin and colleagues acknowledged that they used crude
rates in theirmeta-analysis, but in doing so, the summary es-
timate for the effectiveness of flexible sigmoidoscopy screen-
ing onCRCmortalitywas incorrect. To avoid introducing con-
founding by age, the 2 age groups in NORCCAP should have
been analyzed as separate trials. This approach does not have
a serious effect on the result reported in themeta-analysis be-
cause NORCCAP was a relatively small trial compared with
some of the other trials.
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